$ICU Balance Sheet | Understand Stock

$ICU

$2.52 +$0.05 (2.02%) Close

$ICU Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets (Current Period Unaudited)

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Current assets
Cash
Deferred offering costs
Prepaid insurance and other fees
Other receivables
Accounts receivable, net of allowance for credit losses of $2 and $3, respectively
Inventory
Prepaid expenses
Cash and marketable securities held in trust
Total current assets

Forward option-prepaid forward contracts, net
Other assets
Other assets
Total assets
Accrued expenses
Notes and advances payable - related parties
Deferred underwriting commissions in connection with the initial public offering
Warrant liability (Note 9)
Current liabilities
Accounts payable
Upfront payment for license agreement
Accrued expenses
Contingent upfront payment for license agreement
Contract liabilities
Notes payable, net of deferred financing costs
Convertible notes - related party, net of discount
Convertible notes, current portion
Warrants liability
Forward purchase agreement derivative liability
Liability classified warrants
Total current liabilities

Notes payable, net of deferred financing costs
Government loans
Convertible notes - related party, net of discount, net of current portion
Convertible notes derivative liability, net of current portion
Contract liabilities, net of current portion
Convertible notes, net of current portion
Total liabilities
Class A common stock subject to possible redemption 10,350,000 shares at redemption value of $10.32 and $10.20 per share at September 30, 2022 and December 31, 2021, respectively
Stockholders’ equity
Preferred stock - $0.0001 par value, 10,000,000 shares authorized at June 30, 2026 and December 31, 2025; no shares issued and outstanding at June 30, 2026 and December 31, 2025
Common stock - $0.0001 par value per share; 425,000,000 and 450,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; 4,259,842 and 3,844,613 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
Class A Common Stock
Class B Common Stock
Total common stock - $0.0001 par value per share; 425,000,000 and 450,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; 4,259,842 and 3,844,613 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively

Additional paid-in capital
Accumulated deficit
Class A Common Stock
Class B Common Stock
Total stockholders’ equity
Total liabilities and stockholders’ equity

Comments